Tirofiban HCl

An antiplatelet drug and the glycoprotein IIb/IIIa inhibitor, is indicated for unstable angina in patients with a high risk of developing myocardial infarction. It is administered parenterally. It is also under investigation in patients undergoing coronary angioplasty.

Brands
AGGRASTAT
Adult Dose
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin. . The Molecular Weight of Tirofiban HCl is 495.10.
Contraindications
Tirofiban HCl is contraindicated in conditions like Thrombocytopenia,Hemorrhagic diathesis,Breast feeding,Pain management,Infections in neutropenic patients (in combination with an aminoglycoside).
Effects
The symptomatic adverse reactions produced by Tirofiban HCl are more or less tolerable and if they become severe, they can be treated symptomatically, these include Thrombocytopenia, Bleeding manifestation.
Indications
Tirofiban HCl is primarily indicated in conditions like Gastric acid reduction during anaesthesia, Hyperlipidaemias, Unstable angina.
Interactions
Tirofiban HCl is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAbciximab These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.
Interfrence
Risks
If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Tirofiban should be used with caution in patients with hepatic impairment (avoid if severe); renal impairment; major surgery or severe trauma within 3 months (avoid if within 6 weeks); traumatic or protracted cardiopulmonary resuscitation, organ biopsy or lithotripsy within last 2 weeks; risk of bleeding including peptic ulcer within 3 months; acute pericarditis, aortic dissection, haemorrhagicretinopathy, vasculitis, haematuria, faecal occult blood, severe heart failure, cardiogenic shock, anaemia; puncture of non-compressible vessel within 24 hours; concomittant drugs that increase risk of bleeding (including within 48 hours after thrombolytic); monitor platelet count, haemoglobin and haematocrit before treatment, 2-6 hours after start of treatment and then atleast once daily ; discontinue if thrombolytic therapy, intra-aortic balloon pump or emergency cardiac surgery necessary; discontinue immediately if serious bleeding uncontrolled by pressure occurs; pregnancy (use only if potential benefits outweigh risk) .
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.